〓〓◎Big Fish◎小组◎6GAW◎03月22日作业贴◎〓〓

beenusedUID: 2636942

〓〓◎Big Fish◎小组◎6GAW◎03月22日作业贴◎〓〓

●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○● ●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○● 〓〓◎Big Fish◎小组◎6GAW◎03月22日作业贴◎〓〓 ●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○● ISSUE40 "Scholars and researchers should not be concerned with whether their work makes a contribution to the larger society. It is more important that pursue their individual interesta, however unusual or idiosyncratic those interests may seems." 我们不应该仅仅关注学者和研究者的著作能否对社会做出贡献。 更重要的是关注他们如何追求实现自己的兴趣，  无论那些兴趣显得是多么的非同寻常。 ARGUMENT 5. The following appeared in a memorandum from a dean at Omega University. "Given that the number of people in our country with some form of arthritis is expected to rise from 40 million over the next twenty years, pharmaceutical companies that produce drugs for the treatment of arthritis should be very profitable. Many analysts believe that in ten years Becan Pharmaceuticals, which makes Xenon, the best-selling drug treatment for arthritis, will be the most profitable company. But the patent on Xenon expires in three years, and other companies will then be able to produce a cheaper version of the drug. Thus, it is more likely that in ten years the most profitable pharmaceutical company will be Pekins Pharmaceuticals, maker of a new drug called Xylan, which clincal studies show is perfect over Xenon by seven out of ten patients from the most extreme cases of arthritis." ●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●                                          ★作业说明★ ●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○● 高频写的差不多了，重复第一次作业，大家没写的补上～●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○●○● 温馨提示： 请各位鱼儿在交作业前把作文放入Word里检查一下（如语法和拼写）。 〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓      【Big Fish】小组◎6GAW◎任务总贴◎https://bbs.gter.net/thread-1062787-1-1.html 〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓〓